Further analysis of Lck expression in CLL cells from the patient cohort in relation to either IGHV mutation (Fig. 2c) or disease stage (Fig. 2d) showed no correlation, indicating that Lck levels cannot be used as a surrogate marker for the former and are likely not affected during the course of disease progression. This evidence concerns the gene LCK and B-cell chronic lymphocytic leukemia.